Prelimbic NMDA receptors stimulation mimics the attenuating effects of clozapine on the auditory electrophysiological rebound induced by ketamine withdrawal

Incrocci, Roberta Monteiro; Paliarin, Franciely; Nobre, Manoel Jorge

doi:10.1016/j.neuro.2018.08.013

Cited by 3 publications

(2 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that clozapine can affect 5-HT2A and D4 receptors, increase the release of dopamine, and selectively increase the concentration of Glu in the prefrontal cortex ( Lopez-Munoz and Alamo, 2011). Incrocci et al (2018) stated that the atypical antipsychotic clozapine potently blocked the disruption of the sensorimotor gating induced by NMDA antagonists. Rebollo et al (2018) found that decreasing hypersynchronization in the local circuit may be one of the mechanisms of clozapine in preventing schizophrenia symptoms derived from NMDA hypofunction.…”

Section: Discussionmentioning

confidence: 99%

Effect of Clozapine on Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Psychiatric Symptoms: A Series of Three Cases

Yang

Xia

et al. 2019

Front. Neurosci.

View full text Add to dashboard Cite

The main clinical manifestations of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis are acute or subacute seizures, cognition impairment, and psychiatric symptoms. Nowadays, the scheme of antipsychotic therapy for this disease has not been established. This study reports three cases of anti-NMDAR encephalitis with psychiatric symptoms. The anti-NMDAR antibodies in cerebrospinal fluid (CSF) and serum were positive. The psychiatric symptoms still existed after intravenous immunoglobulin (IVIG) treatment; thus, clozapine was used for antipsychotic therapy. Case 1 was a 37-year-old man who suffered from bad mood and suicide behaviors for 1 month. Hallucination and delusion still existed after IVIG treatment and hormone therapy, and the symptoms were relieved when given clozapine for 12 months. Case 2 was a 28-year-old man who was admitted to our hospital due to injuring other people and destructive behaviors for 2 days. He showed irritability, bad temper, declined cognition, and severe delusion of persecution after IVIG treatment and hormone therapy, but the psychiatric symptoms disappeared when given clozapine for 3 months. Case 3 was a 23-year-old man who suffered from headache and babbing for 7 days. Symptoms such as irritability, bad temper, babbing, and injuring other people still existed after IVIG treatment and hormone therapy, but they disappeared when given clozapine for 2 months. Therefore, we suggest that during the treatment of anti-NMDAR encephalitis with psychiatric symptoms, if the anti-NMDAR antibodies in CSF and serum were positive, and psychiatric symptoms could not be controlled after IVIG and hormone therapy, clozapine may work.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Clozapine on Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Psychiatric Symptoms: A Series of Three Cases

Yang

Xia

et al. 2019

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…In those patients, functional imaging data also suggested activation of the visual cortex in association with structural and connectivity changes (Waters et al., 2014). Based on such clinical evidence and considering the findings of previous studies, investigations were undertaken and revealed that the N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine could induce schizophrenia symptoms, such as visual hallucination (Incrocci et al., 2018), and that the NMDA receptor antagonist MK801 could induce hallucination (Shokry et al., 2019).…”

Section: Introductionmentioning

confidence: 99%

Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder—An evidence from mouse model

et al. 2021

View full text Add to dashboard Cite

Introduction Patients with schizophrenia frequently present with visual disturbances including hallucination, and this symptom is particularly prevalent in individuals with comorbid depressive disorders. Currently, little is known about the neurobiological mechanisms of such psychiatric symptoms, and few explanations for the co‐occurrence of schizophrenia, depression, and visual disturbances are available. Methods In this study, we generated a mouse schizophrenia model in which depressive symptoms were also induced. We adopted in vivo two‐photon calcium imaging and ex vivo electrophysiological recording of the primary visual cortex to reveal the synaptic transmission and neural activity in the mouse schizophrenia model. Results In vivo two‐photon calcium imaging and ex vivo electrophysiological recording of the primary visual cortex revealed impaired synaptic transmission and abnormal neural activity in the schizophrenia model, but not in the depression model. These functional deficits were most prominent in the combined schizophrenia and depression model. Conclusion Overall, our data support a mechanism by which the visual cortex plays a role in visual disturbances in schizophrenia.

show abstract

Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine

Silva-Cardoso

Nobre

2021

Neurochem Res

View full text Add to dashboard Cite

Prelimbic NMDA receptors stimulation mimics the attenuating effects of clozapine on the auditory electrophysiological rebound induced by ketamine withdrawal

Cited by 3 publications

References 89 publications

Effect of Clozapine on Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Psychiatric Symptoms: A Series of Three Cases

Effect of Clozapine on Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Psychiatric Symptoms: A Series of Three Cases

Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder—An evidence from mouse model

Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine

Contact Info

Product

Resources

About